Legal settlements extending market exclusivity of branded drugs near the end of their patent life rose in 2016, a new report from the Federal Trade Commission found, but almost none of those agreements included a monetary payment from branded drugmakers to generic rivals, commonly known as "pay for delay."
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,